Prime/MRx real-world GLP-1 persistence and adherence data published in Journal of Managed Care & Specialty Pharmacy

Since first publishing its industry-leading real-world persistence/adherence and cost-of-care data on glucagon-like peptide-1 (GLP-1) receptor agonists therapies for weight loss in July 2023, Prime Therapeutics/Magellan Rx Management (Prime/MRx) has taken a closer look at the data and presented additional findings at the 2024 Academy of Managed Care Pharmacy (AMCP) Annual Meeting. This extended research has also just been published by the Journal of Managed Care & Specialty Pharmacy (JMCP). 

JMCP is the official peer-reviewed journal of AMCP with a mission “to advance science, expertise, and evidence-based decision-making to improve patient health through access to high-quality, cost-effective medications and other therapies.” 

“As the conversation about GLP-1s continues to evolve, to me it all comes back to the real-world data, and Prime/MRx is proud to continue to be a leading voice on this issue with our ongoing research. It’s an honor to have this research published by JMCP. Congratulations to our Health Outcomes team for this tremendous work.” —David Lassen, Chief Clinical Officer

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended. The research found some GLP-1 products were associated with more people staying on therapy than others; however, low persistence on GLP-1 therapy may include shortages as well as side effects. 

Prime/MRx Clinical and Health Outcomes teams continue to explore this data. Expect additional data to be available soon.